CHRYSALIS: Amivantamab for EGFR exon 20 insertion mutant NSCLC

CHRYSALIS: Amivantamab for EGFR exon 20 insertion mutant NSCLC

ELCC 2023 | Researcher Interview: P. Garrido Lopez Interprets Latest Data from CHRYSALISПодробнее

ELCC 2023 | Researcher Interview: P. Garrido Lopez Interprets Latest Data from CHRYSALIS

Update from CHRYSALIS: amivantamab in patients with NSCLC with MET exon 14 skipping mutationПодробнее

Update from CHRYSALIS: amivantamab in patients with NSCLC with MET exon 14 skipping mutation

Amivantamab in patients with EGFR Ex20ins-mutated NSCLCПодробнее

Amivantamab in patients with EGFR Ex20ins-mutated NSCLC

Amivantamab and lazertinib in treatment-naïve EGFR-mutant NSCLCПодробнее

Amivantamab and lazertinib in treatment-naïve EGFR-mutant NSCLC

Current treatments and challenges for patients with EGFR exon 20 insertion-positive NSCLCПодробнее

Current treatments and challenges for patients with EGFR exon 20 insertion-positive NSCLC

Latest updates in exon 20 insertions focusing on targeted therapies, novel approaches, and impli...Подробнее

Latest updates in exon 20 insertions focusing on targeted therapies, novel approaches, and impli...

WCLC 2020: Updates from the CHRYSALIS trial and what it means for patients with NSCLCПодробнее

WCLC 2020: Updates from the CHRYSALIS trial and what it means for patients with NSCLC